Biomarkers Predict Occult Placental Risk in Diabetes

Pregnancy with pregestational diabetes carries a high risk of fetal complications despite advanced monitoring techniques. Consequently, clinicians struggle to detect early placental insufficiency in these high-risk patients. Recent prospective evidence shows that angiogenic biomarkers can identify occult placental dysfunction effectively. Furthermore, assessing soluble FMS-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) offers crucial clinical insights.

Detecting Occult Placental Dysfunction with Angiogenic Markers

Specifically, a prospective cohort study monitored patients with type 1 and type 2 diabetes from 20 to 36 weeks of gestation. Researchers measured serum sFlt-1 and PlGF levels at four-week intervals. As a result, they identified two distinct temporal patterns of biomarker abnormalities. Early-onset angiogenic imbalance occurred in 26% of participants during the second trimester. Additionally, this early abnormality strongly correlated with adverse perinatal outcomes. Therefore, longitudinal monitoring helps stratify fetal risk independent of ultrasound size measurements.

Clinical Implications for Obstetric Care

Unidentified placental insufficiency often leads to unexpected stillbirth or severe fetal growth restriction. However, routine ultrasound scans may miss subtle metabolic and vascular changes in diabetic placentas. In contrast, serial sFlt-1 and PlGF testing detects underlying vascular pathology early. Moreover, identifying high-risk pregnancies allows obstetricians to step up surveillance and plan timely delivery. Ultimately, integrating angiogenic profiling into routine care promises to improve maternal and neonatal safety.

Frequently Asked Questions

Q1: What are sFlt-1 and PlGF biomarkers?

Soluble FMS-like tyrosine kinase 1 (sFlt-1) is an anti-angiogenic protein, while placental growth factor (PlGF) promotes vascular growth. Therefore, their ratio indicates placental vascular health.

Q2: How does occult placental dysfunction affect diabetic pregnancies?

Occult placental dysfunction causes silent vascular compromise without obvious ultrasound changes. Consequently, it increases the risk of fetal distress, growth restriction, and stillbirth.

Q3: How often should angiogenic biomarkers be measured?

In clinical research, testing serum samples at four-week intervals between 20 and 36 weeks’ gestation effectively identifies early risk patterns.

References

1. Hughes RCE et al. Abnormal serum sFlt-1 and PlGF as markers of occult placental dysfunction and fetal risk in pregestational diabetes: A Prospective Masked Cohort Study. Am J Obstet Gynecol. 2026 Jul 30. doi: undefined. PMID: 42532416.
2. Zeisler H et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13-22.
3. Nuzzo AM et al. Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus. Sci Rep. 2021;11(1):2312.